Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The preclinical results of PT001 in this indication have been very encouraging. The development of this new therapy will directly improve the standard of care for PAH patients by reducing morbidity and enhancing the quality of life at a reasonable cost.
Lead Product(s): Glycopyrronium Bromide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PT001
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2021